8-K
filed May 6, 2026, 7:59 PM ET
ticker URGN
CIK 0001668243
earnings
confidence high
sentiment positive
materiality 0.70
UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share
UroGen Pharma Ltd.
- Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.
- ZUSDURI net revenue $29.2M, 109% sequential growth; 256 unique prescribers as of March 31.
- JELMYTO revenue $21.7M (+7% YoY); FY 2026 guidance reaffirmed at $97–101M.
- Net loss $23.6M ($0.47/share) vs $43.8M ($0.92/share) in Q1 2025; cash $140.3M.
- UGN-103 NDA submission on track for H2 2026; six-month durability data expected mid-2026.
Machine-readable event card
- schema_version
- secwatch.filing_event.v1
- accession
- 0001437749-26-015018
- form_type
- 8-K
- ticker
- URGN
- cik
- 0001668243
- company_name
- UroGen Pharma Ltd.
- filed_at
- 2026-05-06T23:59:59+00:00
- discovered_at
- 2026-05-14T18:02:32.701497+00:00
- generated_at
- 2026-05-14T22:47:20.960830+00:00
- sec_items
- ["2.02", "9.01"]
- event_type
- earnings
- sentiment
- positive
- materiality_score
- 0.7
- calibrated_materiality_score
- 0.7
- confidence
- high
- secwatch_canonical_url
- https://secwatch.observer/filing/0001437749-26-015018
- json_url
- https://secwatch.observer/filing/0001437749-26-015018.json
- markdown_url
- https://secwatch.observer/filing/0001437749-26-015018.md
- text_url
- https://secwatch.observer/filing/0001437749-26-015018.txt
- edgar_index_url
- https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/0001437749-26-015018-index.htm
- edgar_primary_document_url
- https://www.sec.gov/Archives/edgar/data/1668243/000143774926015018/urgn20260504_8k.htm
- generated_by_model
- deepseek-v4-flash:cloud@v2
- review_status
- machine_generated
- human_reviewed
- false
- corrected
- false
- correction_note
- null
- correction_timestamp
- null
- superseded_by
- null
Comparable filings
IVF
INVO Fertility FY2025 revenue $6.84M (+5% YoY); net loss improves to $(5.3)M
INVO Fertility, Inc.
June 2, 2026, 8:40 AM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
and technologies,
today announced fiscal year 2025 financial results. FY2025
Financial Highlights (all metrics compared to FY2024 unless otherwise noted) ● Revenue
was $6,841,250, an increase of 5% compared to $6,532,000. ● Consolidated
clinic revenue increased 4% to $6,721,057, compared to $6,450,431. ● Revenue
from all clinics was $8,021,929, including
Filing page
SEC filing
POLA
Polar Power Q1 net loss narrows 86% to $178K; gross margin expands to 65.7%
Polar Power, Inc.
June 2, 2026, 8:30 AM ET
earnings
Items 2.02, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
Q1 2026 Q1 2025 Y/Y +/(-) Change Net sales $ 1,728 $ 1,723 — Gross profit $ 1,135 $ 320 255 % Gross margin 65.7 % 18.6 % 47.1 pts Total operating expenses $ 1,111 $ 1,421 22 % Income (loss) from operations $ 24 $ (1,101 ) 102 % Net loss $ (178 ) $ (1,265 ) 86 % Net loss per share $ (0.05 ) $ (0.50 ) 90 %
Filing page
SEC filing
CTRN
Citi Trends Q1 sales up 14.4% to $230.9M; adjusted EBITDA doubles to $13.9M
Citi Trends Inc
June 2, 2026, 6:58 AM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
(EXHIBIT 99.1) ---
EX-99.1 2 tm2616574d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 CITITRENDS ANNOUNCES FIRST QUARTER
FISCAL 2026 RESULTS Q1 2026 total sales increased 14.4% to $230.9 million Comparable store sales growth
of 13.9%; Two-year stack of 23.8% Q1 2026 Net Income of $7.8 million;
Q1 2026 adjusted EBITDA* of $13.9 million, more than double Q1 2025 results
Filing page
SEC filing
SIG
Signet Q1 sales $1.6B, SSS +1.8%; raises FY27 adjusted EPS guidance
SIGNET JEWELERS LTD
June 2, 2026, 6:54 AM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
On June 2, 2026, Signet Jewelers Limited (the "Company") issued a press release announcing results for the first quarter ended May 2, 2026.
Filing page
SEC filing
DG
Dollar General Q1 EPS $2.00 beats expectations; raises FY2026 EPS guidance
DOLLAR GENERAL CORP
June 2, 2026, 6:54 AM ET
earnings
Items 2.02, 5.07, 7.01, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
(NYSE: DG) today reported financial results for its first quarter (13 weeks) ended May 1, 2026. First Quarter Fiscal Year 2026
Highlights · Net
Sales Increased 3.4% to $10.8 Billion · Same-Store
Sales Increased 2.0% · Operating
Profit Increased 10.8% to $638.5 Million · Diluted
Earnings Per Share (“EPS”) Increased 12.4% to $2.00 · Cash
Flow From
Filing page
SEC filing
HIVE
HIVE FY2026 revenue $297.8M (+158% YoY); GAAP net loss $148.4M
HIVE Digital Technologies Ltd.
June 2, 2026, 6:23 AM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
EXHIBIT 99.1 HIVE Digital Technologies Ltd.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 HIVE DIGITAL TECHNOLOGIES LTD. HIVE Achieves FY2026 Total Revenue of $297.8 Million (+158% YoY), HIVE's BUZZ HPC Positioned for Growth This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated
Filing page
SEC filing
DCI
Donaldson Q3 FY2026 sales $995.1M (+5.8%), adj. EPS $1.06 (+7.1%)
DONALDSON Co INC
June 1, 2026, 5:41 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
press release is furnished herewith as Exhibit 99.1.
--- EX-99.1 (EX-99.1) ---
Donaldson Reports Record Third Quarter Fiscal 2026 Sales and Earnings Third quarter sales of $995.1 million, up 5.8% Operating margin of 15.6%; All-time high adjusted operating margin of 16.6% GAAP EPS of $1.00; Adjusted EPS of $1.06, up 7.1% Closed margin-accretive Facet acquisition,
Filing page
SEC filing
GMRS
GMR Solutions Q1 revenue $1.46B (+6.6% YoY), net income $106M (+180% YoY), guides FY26 rev $5.9-6.2B
GMR Solutions Inc.
June 1, 2026, 4:45 PM ET
earnings
Items 2.02, 9.01
same fact type: earnings_release
same SEC item: 2.02, 9.01
same event type: earnings
similar materiality
This filing
On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.
Comparable filing
today announced financial results for the first quarter ended March 31, 2026, and full year 2026 financial guidance. First Quarter 2026 Financial Highlights ● Net revenue of $1,457.6 million, up 6.6% compared to $1,367.4 million in the first quarter of 2025 ● Net income of $106.3 million, up 179.7% compared to $38.0 million in the first quarter of 2025 ● Adjusted
Filing page
SEC filing
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.